IR Biosciences Holdings Inc. (IRBS) Stock

About IR Biosciences Holdings Inc.

IR BioSciences Holdings, Inc. is a U.S.-based, early-stage biotechnology firm. Through its subsidiary, ImmuneRegen BioSciences, Inc., it concentrates on researching and developing therapies for significant health challenges, including pulmonary fibrosis, influenza infections, and neutropenia caused by radiation. The company is also actively developing Homspera and its derivatives, Radilex and Viprovex. These compounds are designed to stimulate human stem cells, enhance immune system responses, offer anti-infective properties, serve as vaccine adjuvants, and promote wound healing. Founded in 1999, IR BioSciences Holdings, Inc. maintains its headquarters in Scottsdale, Arizona.

IR Biosciences Holdings Inc. (IRBS) stock trades at $0.00 with a market capitalization of $128122. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, IR Biosciences Holdings Inc. generates a return on equity (ROE) of 38.46% — well above the market average, a sign of a high-quality business, return on capital employed of 44.40%, an operating margin of 0.00%, a net profit margin of 0.00%.